Bieri S, Helg C, Chapuis B, Miralbell R
Oncology Institute of Southern Switzerland, San Giovanni Hospital, Bellinzona, Switzerland.
Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):1071-7. doi: 10.1016/s0360-3016(00)01491-7.
This study was performed to retrospectively assess the potential influence of total-body irradiation (TBI) dose on overall survival in patients undergoing allogeneic bone-marrow transplants (BMT) for hematologic malignancies.
Between October 1984 and December 1996, 116 patients were conditioned with high-dose chemotherapy and fractionated TBI before allogeneic BMT. The median age was 34 years (range 3-60). The TBI dose was given in 6 fractions, twice-a-day, over 3 days before BMT. The total dose was 10 Gy in 24 patients, 12 Gy in 66 patients, and 13.5 Gy in 26 patients.
TBI dose was inversely correlated with overall survival. Five-year survival was 62% for patients conditioned with 10 Gy, 55% for patients conditioned with 12 Gy, and 46% for patients conditioned with 13.5 Gy. Age at BMT was also independently correlated with survival, with the best outcome for patients < 40 years old.
A TBI dose (fractionated) > 10 Gy may not necessarily be associated with a better outcome in patients undergoing allogeneic bone-marrow transplant for hematologic malignancies.
本研究旨在回顾性评估全身照射(TBI)剂量对接受异基因骨髓移植(BMT)治疗血液系统恶性肿瘤患者总生存期的潜在影响。
1984年10月至1996年12月期间,116例患者在异基因BMT前接受了大剂量化疗和分次TBI预处理。中位年龄为34岁(范围3 - 60岁)。TBI剂量在BMT前3天内分6次给予,每天2次。24例患者的总剂量为10 Gy,66例患者为12 Gy,26例患者为13.5 Gy。
TBI剂量与总生存期呈负相关。接受10 Gy预处理的患者5年生存率为62%,接受12 Gy预处理的患者为55%,接受13.5 Gy预处理的患者为46%。BMT时的年龄也与生存率独立相关,<40岁的患者预后最佳。
对于接受异基因骨髓移植治疗血液系统恶性肿瘤的患者,分次TBI剂量>10 Gy不一定能带来更好的预后。